Overall Survival
CPS
In KEYNOTE-059, median OS was 10 months in all patients and in the CPS ≥ 1 population (Fig. Kaplan–Meier estimates of overall survival in Japanese patients from In the CPS ≥ 1 population of KEYNOTE-061, median OS (pembrolizumab vs. chemotherapy) was 12 versus 10 months (HR, 0.67; 95% CI, 0.39–1.15); after adjusting for selected baseline characteristics in a multivariate analysis, the HR was 0.71 (95% CI, 0.40–1.25). In the CPS ≥ 10 population, median OS (pembrolizumab vs. chemotherapy) was 10 versus 18 months (HR, 2.06; 95% CI, 0.63–6.78) (Fig. In the CPS ≥ 1 population of KEYNOTE-062, median OS (pembrolizumab vs. chemotherapy) was 20 versus 18 months (HR, 0.76; 95% CI, 0.43–1.33) (Fig. 